As of 2025-05-21, the Relative Valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (44.15) USD. This relative valuation is based on P/E multiples. With the latest stock price at 44.88 USD, the upside of Tarsus Pharmaceuticals, Inc. based on Relative Valuation is -198.4%.
The range of the Relative Valuation is (38.57) - (42.87) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.2x | 17.0x |
| Forward P/E multiples | 15.4x - 19.1x | 18.4x |
| Fair Price | (38.57) - (42.87) | (44.15) |
| Upside | -185.9% - -195.5% | -198.4% |
| Date | P/E |
| 2025-05-15 | -17.21 |
| 2025-05-14 | -17.17 |
| 2025-05-13 | -16.60 |
| 2025-05-12 | -17.69 |
| 2025-05-09 | -17.92 |
| 2025-05-08 | -18.87 |
| 2025-05-07 | -18.95 |
| 2025-05-06 | -18.59 |
| 2025-05-05 | -19.22 |
| 2025-05-02 | -18.96 |
| 2025-05-01 | -20.14 |
| 2025-04-30 | -20.78 |
| 2025-04-29 | -20.38 |
| 2025-04-28 | -19.90 |
| 2025-04-25 | -20.02 |
| 2025-04-24 | -20.00 |
| 2025-04-23 | -20.02 |
| 2025-04-22 | -19.79 |
| 2025-04-21 | -19.42 |
| 2025-04-17 | -19.72 |
| 2025-04-16 | -19.77 |
| 2025-04-15 | -19.66 |
| 2025-04-14 | -19.50 |
| 2025-04-11 | -18.59 |
| 2025-04-10 | -17.66 |
| 2025-04-09 | -18.36 |
| 2025-04-08 | -17.87 |
| 2025-04-07 | -19.01 |
| 2025-04-04 | -18.82 |
| 2025-04-03 | -19.84 |
| 2025-04-02 | -20.61 |
| 2025-04-01 | -19.58 |
| 2025-03-31 | -20.56 |
| 2025-03-28 | -20.71 |
| 2025-03-27 | -20.28 |
| 2025-03-26 | -20.42 |
| 2025-03-25 | -20.55 |
| 2025-03-24 | -20.96 |
| 2025-03-21 | -20.00 |
| 2025-03-20 | -19.98 |
| 2025-03-19 | -19.84 |
| 2025-03-18 | -18.48 |
| 2025-03-17 | -19.01 |
| 2025-03-14 | -19.25 |
| 2025-03-13 | -18.60 |
| 2025-03-12 | -18.85 |
| 2025-03-11 | -18.87 |
| 2025-03-10 | -17.85 |
| 2025-03-07 | -18.60 |
| 2025-03-06 | -17.44 |